Company Focus
Lundbeck
Latest Lundbeck News
Latest Lundbeck News
Pharmaceutical
For years, AI in pharma largely remained in the innovation phase. Companies ran pilot programs, formed partnerships and showcased demonstrations, but there was limited impact on how organizations were structured, how teams worked or how decisions were made. 11 March 2026
Pharmaceutical
Danish neuroscience specialist Lundbeck has appointed Markus Kede as senior vice president and chief AI officer, creating a new executive role to accelerate the company’s use of artificial intelligence across research and commercial operations. 10 March 2026
Biotechnology
Danish CNS specialist Lundbeck has announced positive results from the multiple IV dosing part of PROCEED, an adaptive Phase IIb dose-finding and route of administration trial of bocunebart (Lu AG09222). 13 February 2026
Pharmaceutical
Danish CNS specialist Lundbeck has reported fourth-quarter and 2025 financial results. 4 February 2026
Biotechnology
Danish CNS company Lundbeck announced six-month data from the 12-month, real-world INFUSE study, evaluating the effectiveness of Vyepti (eptinezumab) in adults with migraine who had failed at least one preventive anti-calcitonin gene–related peptide (aCGRP) treatment, at any time point previously. 31 January 2026
Latest CNS News & Features
Latest CNS News
Insights
Company Spotlight
Annovis Bio is a Phase III clinical-stage biotechnology company developing buntanetap, an oral therapy targeting multiple neurotoxic proteins implicated in Alzheimer's and Parkinson's disease.
Latest News & Features of interest to Lundbeck
Pharmaceutical
The local unit of US biotech major Biogen today announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization to the high dose regimen (50/28mg) of Spinraza (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA). 14 April 2026
Biotechnology
Important news last week kicked off with Neurocrine Biosciences announcing a proposed $2.9 billion takeover bid for Solena Therapeutics. Then Gilead Sciences revealed an up to $5 billion takeover for German antibody-drug conjugate (ADCs) developer Tubulis. Also of note, Sanofi released mixed Phase II results for its asthma and dermatology candidate lunsekimig. The US Food and Drug Administration (FDA) announced plans for greater control of direct-to-consumer Rx medicines advertising. 12 April 2026
Pharmaceutical
German pharma Boehringer Ingelheim has handed full commercial and marketing rights for digital schizophrenia therapy CT-155 to US-based Click Therapeutics, reshaping a partnership first struck in 2020. 10 April 2026
Pharmaceutical
USA-based neurodegenerative disorders specialist Annovis Bio today revealed that it has secured financing to support the development of its investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. 10 April 2026
Biotechnology
Privately-held Alloy Therapeutics, a biotech ecosystem company promising to democratize access to new drug discovery technologies, has announced a collaboration and license agreement with US biotech major Biogen. 8 April 2026
Biotechnology
German drug developer Evotec reported fourth-quarter 2025 revenue of $293 million, up 14%, and adjusted EBITDA of $67 million, up 103%, driven largely by a license payment linked to the sale of its Toulouse biologics site to Sandoz. 8 April 2026
Biotechnology
Shares of Swiss biopharma AC Immune were up nearly 7%, at $2.88 by mid-morning, after it revealed an amendment to its collaboration with US pharma giant Eli Lilly. 7 April 2026
Biotechnology
US drug developer Denali Therapeutics on Friday revealed it has received notification from Japan’s Takeda of its decision to terminate the collaboration agreement between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN). 7 April 2026
Pharmaceutical
Independent French pharma major Servier announced that the UK’s National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Voranigo (vorasidenib). 3 April 2026
Pharmaceutical
Precision oncology start-up Fore Biotherapeutics announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to plixorafenib for the treatment of adult patients with BRAF V600E-mutated high-grade glioma (HGG). 2 April 2026
Latest In Brief for Lundbeck
Pharmaceutical
Israel-based generics giant Teva Pharmaceutical Industries and France’s Medincell announced that the US Food and Drug Administration has accepted the New Drug Application for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. 21 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze